Resources VIDEOS 01:22 What is the leading cause of death in patients with type 2 diabetes? 02:44 Reduction in CV death 02:11 Are patients with T2D at elevated CV risk? 02:35 What are the main considerations when choosing a medication for patients with type 2 diabetes? 01:18 Idarucizumab (Praxbind®) Administration Video 02:00 New Dabigatran etexilate (Pradaxa®) Capsule Color 00:32 Life happens: Car accidents 00:49 Life happens: How emergency situations affect life of patients on OAC treatment 00:42 Life happens: Appendicitis is one of the most frequent abdominal surgical emergencies 01:29 Idarucizumab (Praxbind®) patient case in gallbladder removal 03:11 REVERSE-AD study 03:00 Idarucizumab (Praxbind®) real patient cases 06:12 Reversibility of NOAC therapies: the neurologist's perspective 02:14 RE-DUAL PCI video 06:52 NOAC safety in clinical practice: Evidence from the real world 03:33 US Department of Defense Healthcare Database 06:52 Mode of Action of Idarucizumab (Praxbind®) 02:01 The influence of the EMPA-REG Outcome trial results on T2D management 01:59 How Empagliflozin (Jardiance®) differs from other SGLT2 inhibitors 0:43 Appropriate dose of many medications needs to be carefully considered in T2D patients 0:47 DPP4i - with the exception of linagliptin - need to be dose adjusted based on renal function decline 0:39 Complexity of T2D treatment accounts for not appropriately adjusting doses 0:37 Simplification of T2D therapy with Linagliptin (Trajenta®): 5mg once daily, the same dose regardless of renal function 0:42 Linagliptin (Trajenta®): comparable efficacy within DPP4i and a simple way to keep patients on a licensed dose 0:34 Linagliptin (Trajenta®): no extra monitoring of renal function for the sake of dose adjustment 0:41 Linagliptin (Trajenta®) has the benefits of the DPP4i class plus no dose reduction regardless of renal function 1:36 Fixed dose combinations of metformin and DPP4i: importance of renal function monitoring 0:48 FDC metformin with linagliptin (TRAJENTA DUO®): the only DPPP4i that does not require dose reduction when renal function declines 1:27 FDC metformin with linagliptin (TRAJENTA DUO®): the only DPP4i you can maintain on the same daily dose when renal function declines 0:29 Linagliptin (Trajenta®): proven HbA1c reduction with the same dose at any stage of renal function 0:44 Linagliptin (Trajenta®) benefits: proven efficacy, ease of use: one dose, regardless of renal function 1:06 Linagliptin (Trajenta®) has demonstrated high efficacy on a broad range of T2D populations regardless of renal function 0:56 Linagliptin (Trajenta®) makes life easier for GPs as well as patients 1:03 Linagliptin (Trajenta®): A simple way to keep your patients on a licensed dose when administered as appropriate: 5 mg OD 0:55 Linagliptin (Trajenta®) can be used even before renal function declines 1:00 Not having to dose adjust can simplify therapy for complex T2D patients 0:45 T2D is complex and adjustment of medication dose is an additional thing to think about 01:24 Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Load more Clinical studies EMPA-REG Outcome study result Empagliflozin (Jardiance®) Prescribing Information Empagliflozin Metformin HCI (Jardiance Duo®) Prescribing Information FDA advisory RE-DUAL PCI Low-Dose NOAC Usage: A Closer Look Dabigatran etexilate (Pradaxa®) Prescribing Information Idarucizumab (Praxbind®) Prescribing information Randomised Controlled Trials vs Real World Evidence Linagliptin (Trajenta®) Prescribing Information Linagliptin Metformin HCl (Trajenta Duo®) Prescribing Information South Korea Real World Data Singapore Real World Data RealGiDo - Real-world study on dose adjustment Afatinib (Giotrif®) Package Insert Load more